BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30701541)

  • 21. Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma.
    El-Mallawany NK; Cairo MS
    Clin Adv Hematol Oncol; 2015 Feb; 13(2):113-23. PubMed ID: 25774481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Uncommon non-Hodgkin lymphomas of childhood: pathological diagnosis, clinical features and treatment approaches.
    Sandlund JT; Perkins SL
    Br J Haematol; 2015 Jun; 169(5):631-46. PubMed ID: 25851546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breakthrough therapies in B-cell non-Hodgkin lymphoma.
    Cheah CY; Fowler NH; Wang ML
    Ann Oncol; 2016 May; 27(5):778-87. PubMed ID: 26802148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The evolving role of lenalidomide in non-Hodgkin lymphoma.
    Galanina N; Petrich A; Nabhan C
    Leuk Lymphoma; 2016 Jul; 57(7):1507-16. PubMed ID: 26902680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adolescent and young adult non-Hodgkin lymphoma.
    Hochberg J; El-Mallawany NK; Abla O
    Br J Haematol; 2016 May; 173(4):637-50. PubMed ID: 27071675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Childhood, adolescent and young adult non-Hodgkin lymphoma: current perspectives.
    Cairo MS; Beishuizen A
    Br J Haematol; 2019 Jun; 185(6):1021-1042. PubMed ID: 30729513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 2: adoptive cellular immunotherapy, small-molecule inhibitors, and immunomodulation.
    Siddiqi T; Rosen ST
    Oncology (Williston Park); 2015 Apr; 29(4):299-308. PubMed ID: 25920929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Innovative strategies in lymphoma therapy.
    Jäger U
    Wien Klin Wochenschr; 2003 Aug; 115(13-14):462-70. PubMed ID: 13677264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children.
    Giulino-Roth L; Goldman S
    Br J Haematol; 2016 May; 173(4):531-44. PubMed ID: 26996160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma.
    Waibel M; Gregory G; Shortt J; Johnstone RW
    Curr Opin Hematol; 2014 Jul; 21(4):297-308. PubMed ID: 24811162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New drugs for the treatment of non-Hodgkin lymphomas.
    Smith SM
    Chin Clin Oncol; 2015 Mar; 4(1):14. PubMed ID: 25841721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
    Michot JM; Lazarovici J; Ghez D; Danu A; Fermé C; Bigorgne A; Ribrag V; Marabelle A; Aspeslagh S
    Eur J Cancer; 2017 Nov; 85():67-77. PubMed ID: 28892775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).
    Golding B; Luu A; Jones R; Viloria-Petit AM
    Mol Cancer; 2018 Feb; 17(1):52. PubMed ID: 29455675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary Mediastinal Nodal and Extranodal Non-Hodgkin Lymphomas: Current Concepts, Historical Evolution, and Useful Diagnostic Approach: Part 2.
    Piña-Oviedo S; Moran CA
    Adv Anat Pathol; 2019 Nov; 26(6):371-389. PubMed ID: 31567129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in cellular and humoral immunotherapy - implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma.
    Chu Y; Gardenswartz A; Termuhlen AM; Cairo MS
    Br J Haematol; 2019 Jun; 185(6):1055-1070. PubMed ID: 30613939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-Hodgkin Lymphoma in Children.
    Sandlund JT
    Curr Hematol Malig Rep; 2015 Sep; 10(3):237-43. PubMed ID: 26174528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.
    Barth MJ; Chu Y; Hanley PJ; Cairo MS
    Br J Haematol; 2016 May; 173(4):597-616. PubMed ID: 27062282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histamine-releasing factor/translationally controlled tumor protein plays a role in induced cell adhesion, apoptosis resistance and chemoresistance in non-Hodgkin lymphomas.
    He S; Huang Y; Wang Y; Tang J; Song Y; Yu X; Ma J; Wang S; Yin H; Li Q; Ji L; Xu X
    Leuk Lymphoma; 2015 Jul; 56(7):2153-61. PubMed ID: 25363345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Targeted therapies in the management of malignant lymphoma - is the end of conventional chemotherapy near?].
    Hellmuth JC; Koch R; Weigert O
    Dtsch Med Wochenschr; 2024 May; 149(11):621-629. PubMed ID: 38749438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnosis and management of rare paediatric Non-Hodgkin lymphoma.
    Xavier AC; Suzuki R; Attarbaschi A
    Best Pract Res Clin Haematol; 2023 Mar; 36(1):101440. PubMed ID: 36907633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.